Faculty Collaboration Database

Assessment of expression profile of microRNAs in multiple sclerosis patients treated with fingolimod. J Mol Neurosci 2020 Aug;70(8):1274-1281

Date

03/28/2020

Pubmed ID

32215780

DOI

10.1007/s12031-020-01537-4

Scopus ID

2-s2.0-85082950017 (requires institutional sign-in at Scopus site)   5 Citations

Abstract

Fingolimod is an immunotherapeutic drug approved in certain countries as first-line therapy for relapsing-remitting multiple sclerosis (RRMS). The drug has been shown to alter the expression of several coding and non-coding genes. In the current study, we assessed the expression of miR-506-3p, miR-217, miR-381-3p, miR-1827, miR-449a and miR-655-3p in peripheral blood of patients with RRMS undergoing treatment with fingolimod compared with healthy controls. We also compared the expression of these miRNAs between fingolimod responders and non-responders to determine their relevance with regard to response to fingolimod. Expression of miR-381-3p was significantly higher in responders than in controls (RE difference = 3.903, P = 0.005), while expression of miR-655-3p was significantly lower in both responders and non-responders compared with controls (RE difference = -1.03, P = 0.014; RE difference = -1.41, P < 0.0001, respectively). No difference was found in the expression of other miRNAs between study subgroups. In addition, there was no significant difference in the expression of any miRNA between responders and non-responders. Although there were significant pairwise correlations between expression levels of all of the assessed miRNAs in controls, MS patients exhibited differences in correlation patterns. Expression of miR-381-3p was correlated with age in responders. However, expression of other miRNAs did not correlate with age in any study subgroup. The current study indicates a possible role for miR-655-3p and miR-381-3p in the pathogenesis of MS or possible effects of fingolimod on the expression of these miRNAs. Future studies are needed to verify these results in larger patient populations.

Author List

Mazdeh M, Kordestani H, Komaki A, Eftekharian MM, Arsang-Jang S, Branicki W, Taheri M, Ghafouri-Fard S

Author

Shahram Arsang-Jang Postdoctoral Fellow in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Biomarkers
Female
Fingolimod Hydrochloride
Humans
Immunosuppressive Agents
Male
MicroRNAs
Middle Aged
Multiple Sclerosis
Treatment Outcome